Your Messages Inbox (0) 
See AllYour Article Summary
FDA Approves Labeling Update for REYATAZ (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
Bristol Myers-Squibb Company, 11/06/09
Bristol–Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long–term data from the CASTLE Study. The CASTLE Study assessed a once–daily REYATAZ/ritonavir (REYATAZ/r)–based regimen versus a twice–daily lopinavir/ritonavir (LPV/r)–based regimen in previously untreated adult patients infected with HIV–1.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
XenoPort, 11/23/09
Article Search
Sponsor